Comparison

KPV vs. Thymosin Alpha-1

Two peptides side-by-side — identity, evidence base, legal status and known adverse events.

Identity

Mechanism of action

KPV

KPV is the C-terminal fragment of α-melanocyte-stimulating hormone (α-MSH). In preclinical models the inflammation-modulating activity is attributed predominantly to inhibition of the NF-κB and MAP-kinase signalling pathways, accompanied by reduced release of pro-inflammatory mediators. Cellular uptake via the peptide transporter PepT1 has also been described. The precise molecular mechanisms are not conclusively understood and not confirmed in humans.

Thymosin Alpha-1

Thymosin Alpha-1 is an N-terminally acetylated peptide originally isolated from the thymus. It modulates T-lymphocyte maturation and function and acts on dendritic cells via Toll-like receptors (TLR9 / TLR2). In preclinical and some clinical studies, increased interferon-gamma responses and altered T-cell subpopulations have been reported.

Evidence base

Highest evidence

Animal model

Human RCT

Studies

of which in humans

Effects recorded

Open conflicts

Documented adverse events

Legal status

Country	KPV	Thymosin Alpha-1
Germany	Unapproved	Unapproved
IT	—	Prescription
United States	Research only	Unapproved

Full entries

Frequently asked questions

What is the difference between KPV and Thymosin Alpha-1?: KPV is classified as "Healing", while Thymosin Alpha-1 is classified as "Healing". KPV: KPV is the C-terminal tripeptide (lysine-proline-valine) of the hormone α-MSH, corresponding to its positions 11–13. In cell and rodent models an inflammation-modulating activity has been described, primarily via inhibition of the NF-κB signalling pathway. The evidence is drawn almost exclusively from preclinical work (cell culture and mouse); controlled human studies are essentially absent. KPV is not an approved medicinal product. Thymosin Alpha-1: Synthetic 28-amino-acid peptide identical to a naturally occurring thymus peptide. Approved as Zadaxin in more than 30 countries (not US/EU) for hepatitis B treatment and as an immunomodulator. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
Which peptide is better supported by science, KPV or Thymosin Alpha-1?: The highest available evidence level is "Animal model" for KPV and "Human RCT" for Thymosin Alpha-1. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
What is the legal status of KPV and Thymosin Alpha-1 in Germany and the United States?: Germany: KPV — Unapproved, Thymosin Alpha-1 — Unapproved. United States: KPV — Research only, Thymosin Alpha-1 — Unapproved. These are factual summaries with source and review date on the individual pages.

Country

KPV

Thymosin Alpha-1

Germany

Unapproved

—

Prescription

United States

Research only

Unapproved

Frequently asked questions

What is the difference between KPV and Thymosin Alpha-1?

KPV is classified as "Healing", while Thymosin Alpha-1 is classified as "Healing". KPV: KPV is the C-terminal tripeptide (lysine-proline-valine) of the hormone α-MSH, corresponding to its positions 11–13. In cell and rodent models an inflammation-modulating activity has been described, primarily via inhibition of the NF-κB signalling pathway. The evidence is drawn almost exclusively from preclinical work (cell culture and mouse); controlled human studies are essentially absent. KPV is not an approved medicinal product. Thymosin Alpha-1: Synthetic 28-amino-acid peptide identical to a naturally occurring thymus peptide. Approved as Zadaxin in more than 30 countries (not US/EU) for hepatitis B treatment and as an immunomodulator. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.

Which peptide is better supported by science, KPV or Thymosin Alpha-1?

The highest available evidence level is "Animal model" for KPV and "Human RCT" for Thymosin Alpha-1. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.

What is the legal status of KPV and Thymosin Alpha-1 in Germany and the United States?

Germany: KPV — Unapproved, Thymosin Alpha-1 — Unapproved. United States: KPV — Research only, Thymosin Alpha-1 — Unapproved. These are factual summaries with source and review date on the individual pages.